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Abstract
Background: Sox6 is a multi-faceted transcription factor involved in the terminal differentiation of many different
cell types in vertebrates. It has been suggested that in mice as well as in zebrafish Sox6 plays a role in the terminal
differentiation of skeletal muscle by suppressing transcription of slow fiber specific genes. In order to understand
how Sox6 coordinately regulates the transcription of multiple fiber type specific genes during muscle
development, we have performed ChIP-seq analyses to identify Sox6 target genes in mouse fetal myotubes and
generated muscle-specific Sox6 knockout (KO) mice to determine the Sox6 null muscle phenotype in adult mice.
Results: We have identified 1,066 Sox6 binding sites using mouse fetal myotubes. The Sox6 binding sites were
found to be associated with slow fiber-specific, cardiac, and embryonic isoform genes that are expressed in the
sarcomere as well as transcription factor genes known to play roles in muscle development. The concurrently
performed RNA polymerase II (Pol II) ChIP-seq analysis revealed that 84% of the Sox6 peak-associated genes
exhibited little to no binding of Pol II, suggesting that the majority of the Sox6 target genes are transcriptionally
inactive. These results indicate that Sox6 directly regulates terminal differentiation of muscle by affecting the
expression of sarcomere protein genes as well as indirectly through influencing the expression of transcription
factors relevant to muscle development. Gene expression profiling of Sox6 KO skeletal and cardiac muscle revealed
a significant increase in the expression of the genes associated with Sox6 binding. In the absence of the Sox6
gene, there was dramatic upregulation of slow fiber-specific, cardiac, and embryonic isoform gene expression in
Sox6 KO skeletal muscle and fetal isoform gene expression in Sox6 KO cardiac muscle, thus confirming the role
Sox6 plays as a transcriptional suppressor in muscle development.
Conclusions: Our present data indicate that during development, Sox6 functions as a transcriptional suppressor of
fiber type-specific and developmental isoform genes to promote functional specification of muscle which is critical
for optimum muscle performance and health.
Background
Skeletal muscle in vertebrates has evolved to be a major
organ system with great adaptability in order to respond
to constantly changing physical demands placed upon it.
This adaptability is achieved by the ability of muscle
fibers to change their contractile and metabolic proper-
ties. Adult skeletal muscle consists of two major fiber
groups, slow-twitch and fast-twitch. In general, slow
fibers are best fit for long-lasting aerobic activity
whereas fast fibers are best fit for short bouts of anaero-
bic activity [1]. At the molecular level, a coordinated
expression of multiple fiber type-specific genes, both
structural and enzymatic, is required to give each fiber
type its unique characteristics. Slow and fast muscle
fibers are operationally defined by the expression of the
isoforms of myosin heavy chain (MyHC) [2]. In adult
rodent skeletal muscle, slow fibers are defined by the
expression of MyHC-b, whereas fast fibers are defined
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and IIb (contractive speed: IIa<IIx/d<IIb) [3]. In devel-
oping fetal rodent muscle, instead of MyHC-IIa, IIx/d,
and IIb, there are two developmental MyHC isoforms
(embryonic and perinatal) that are expressed, along with
MyHC-b, at different stages of development [4,5]. After
birth, expression of embryonic and perinatal MyHC iso-
forms as well as MyHC-b is significantly downregulated
and the majority of the rodent muscle becomes fast
MyHC-expressing fibers with exception of weight bear-
ing core muscles such as soleus where slow MyHC-b is
highly expressed [5-7]. In adult muscle, the main deter-
minant of muscle fiber type is motoneuron input
[3,8-11]. Several mediators and transcription factors
have been identified for the nerve dependent fiber type
regulation in adult skeletal muscle [3]. In contrast, our
knowledge about factors that regulate fiber type differ-
entiation during skeletal muscle development is still lim-
ited. We have previously reported that Sox6 mutant fetal
and perinatal skeletal muscle exhibits a significant
increase in slow fiber type-specific gene expression
accompanied by a significant decrease in fast fiber type-
specific gene expression [12,13]. Based on these observa-
tions, we have proposed that Sox6 functions as a tran-
scriptional suppressor of slow fiber specific genes in
developing skeletal muscle.
Sox6 is a member of the evolutionarily highly con-
served Sox transcription factor family [14-17]. Between
mice and humans, the overall amino acid sequence of
the Sox6 protein is approximately 95% conserved, and
the functional domains are 100% conserved [18]. The
Sox proteins contain the Sry-related HMG box domain
which mediates sequence-specific DNA binding [16,17].
In general, the specificity of Sox protein targets in each
cell type is regulated by their cofactors [16,19], a prop-
erty that is especially important for the Sox6 protein
since it lacks a regulatory domain (activator or repres-
sor). Therefore, when Sox6 is involved in transcriptional
regulation, cofactors of Sox6 dictate whether the out-
come is activation or repression [15,16]. For example,
Sox6 activates cartilage specific gene transcription as
part of the Sox trio proteins (Sox5, Sox6 and Sox9)
[20-22]. In other cell types, Sox6 suppresses transcrip-
tion of the fgf3 gene or the cyclinD1 gene by associating
with repressors [23,24]. In the case of skeletal muscle,
we have shown that Sox6 suppresses transcription of
slow fiber specific genes during development, thus play-
ing a critical role in initial muscle fiber type differentia-
tion [12,13].
In the present study, to start to uncover how Sox6
regulates transcription of fiber type specific genes at the
molecular level, we used a conditional Sox6 allele [25]
to inactivate Sox6 in developing skeletal muscle. The
muscle specific inactivation of Sox6 allowed us to
overcome the perinatal lethality of Sox6 mutant mice
[26,27] and obtain Sox6 knockout (KO) adult skeletal
muscle for in-depth analysis. To identify Sox6 target
genes and assess their transcriptional status, we con-
ducted ChIP-seq analyses using Sox6 and RNA polymer-
ase II (Pol II) antibodies. Combining these methods, we
demonstrate that: (1) Inactivation of Sox6 results in an
extreme upregulation in expression of slow fiber speci-
fic, cardiac and fetal isoform genes, suggesting that Sox6
is required for the functional maturation of skeletal
muscle, and (2) Sox6 binds to the DNA sequences in
the vicinity of these genes, and thus is directly involved
in the transcriptional suppression of its target genes.
These results indicate that Sox6 plays a critical role in
functional specification of muscle during development.
Results
The expression level of MyHC-b is dramatically increased
in Sox6 KO muscle during development
We have previously shown that in the Sox6 null fetal
skeletal muscle, nascent fast muscles maintain slow
MyHC-b expression [13]. In addition to MyHC-b,o t h e r
slow fiber specific genes (e.g. Tnnc1, Tnni1, Tnnt1,a n d
Myl2) are also upregulated in the Sox6 null muscle,
along with significant downregulation of multiple fast
fiber specific genes [12,13]. Based on these results, we
proposed that Sox6 functions as a suppressor of slow
fiber specific genes, thus the loss of Sox6 leads to an
increase in slow muscle fibers. Since Sox6 null muta-
tions cause early postnatal lethality [26,27], we were
unable to determine whether this Sox6 null fetal pheno-
type is maintained through postnatal development. To
overcome the lethal phenotype, we utilized mice carry-
ing a Sox6 conditional allele [25] to inactivate Sox6 spe-
cifically in skeletal muscle. To start assessing the
phenotype of adult Sox6 KO muscle, we first used the
Myf5-Cre mouse [28]. In this Cre-transgenic mouse, the
Cre recombinase under the control of the Myf5 promo-
ter is expressed very early in the skeletal muscle lineage
(starting at approximately E8 in somites); therefore, the
inactivation of Sox6 occurs significantly earlier than the
beginning of fiber type specification [4,5]. To conduct a
comprehensive analysis of the Sox6 KO muscle pheno-
type, we examined four different muscles in the hin-
dlimb, the tibialis anterior (TA, fast), extensor digitorum
longus (EDL, fast), gastrocnemius (fast), and soleus
(slow) [6]. The mRNA expression of the following four
genes: slow MyHC-b (Myh7), fast MyHC-IIb (Myh4),
peroxisome proliferative activated receptor g coactivator
1a (Ppargc1a), and succinate dehydrogenase complex
subunit A (Sdha) were determined by reverse transcrip-
tion-quantitative PCR (RT-qPCR) and compared
between Sox6 KO (Sox6
f/f; Myf5-Cre) and control
(Sox6
f/f)m i c e .A ss u m m a r i z e di nT a b l e1 ,S o x 6
An et al. BMC Developmental Biology 2011, 11:59
http://www.biomedcentral.com/1471-213X/11/59
Page 2 of 21inactivation caused a significant increase in the mRNA
expression of Myh7 and a concurrent decrease in Myh4
in the TA, EDL, and gastrocnemius muscles. The Sox6
KO soleus muscle showed the least change in expression
of these two MyHC isoforms (Table 1). This result likely
reflects the observation that Sox6 expression in soleus is
significantly lower than the other three fast muscles
(Additional file 1, Figure S1A), therefore, Sox6 inactiva-
tion may have had a less impact in soleus compared to
the other muscles. Regarding the Sox6 inactivation levels
in adult muscle, we noticed that a higher level of Sox6
inactivation, determined by Sox6 mRNA level, did not
necessarily correlate with an increase in Myh7 mRNA
level. There are a few possible hypotheses to explain
this observation. First, Sox6 is not a muscle specific
gene and is also expressed in fibroblasts, which can
obscure an accurate quantification of Sox6 mRNA speci-
fic to muscle cells. Second, the Sox6 mutation is reces-
sive in nature. Therefore, although two independent
Sox6 KO muscle samples show 50% reduction in Sox6
mRNA level, one sample may have more homozygous
S o x 6n u l lc e l l sa n dt h eo t h e rm a yh a v em o r eh e t e r o z y -
gous cells, leading to a significant difference in Myh7
expression. Third, skeletal muscle is multinucleated,
which adds another layer of complexity as to how Sox6
inactivation in each nucleus influences Myh7 expression
in a myotube as a whole.
To sort out these issues, we performed immunohisto-
chemistry to examine the Sox6 and Myh7 (MyHC-b)
protein expression at the cellular level in fetal, early post-
natal and adult muscle. We focused our observation on
the TA-EDL region, composed of fast-twitch myofibers
in the adult mouse. As shown in Figure 1A, in E18.5 con-
trol (Sox6
f/f), nuclear Sox6 staining was well correlated
with the absence of cytoplasmic MyHC-b staining. Also
at P7, the presence of Sox6 nuclear staining corre-
sponded to MyHC-b negative myotubes (Figure 1B). In
Sox6 KO muscle (Sox6
f/f;M y f 5 - C r e ) ,a tb o t hs t a g e s ,
nearly 100% of myofibers displayed MyHC-b expression
(Figures 1A and 1B). These data show that Sox6 expres-
sion does not coincide with slow-twitch fiber gene
expression, supporting our idea that Sox6 functions as a
suppressor of the slow-twitch fiber gene program. There-
fore, at the protein level, the loss of Sox6 expression
clearly leads to upregulation of MyHC-b during the early
stages of muscle development. During the normal mouse
fast muscle development, the number of MyHC-b posi-
tive slow-twitch fibers significantly decreases as postnatal
skeletal muscles functionally mature [3]. We observed
this trend in the developing control mouse muscles (Fig-
ures 1A and 1B), resulting in adult TA-EDL muscle with
extremely rare MyHC-b positive myofibers (Figure 1C).
In contrast to the control, at E18.5 and P7, nearly all
Sox6 KO myofibers were MyHC-b positive (Figures 1A
and 1B), indicating that at these early stages, muscle-spe-
cific Sox6 inactivation led to extensive upregulation of
MyHC-b expression in the entire Sox6 KO muscle. In
the adult Sox6 KO muscle, on the other hand, approxi-
mately 50% of myofibers were MyHC-b positive, a signifi-
cant increase compared to the control (Figure 1C, Sox6
f/
f); however a significant decrease compared to the P7
Sox6 KO muscle (Figure 1B, Sox6
f/f;M y f 5 - C r e ) .W h e n
Sox6 staining signals in the control and Sox6 KO adult
muscles were compared, overall Sox6 staining signals
were lower in Sox6 KO, however, it was hard to make a
clear correlation with MyHC-b staining, since Sox6 stain-
ing in adult muscle was quite diffused (Figure 1C, Sox6
f/
f). In light of this, we noticed that in control P7 muscle,
some MyHC-b-negative myofibers did not show nuclear
Sox6 staining, but rather dispersed cytoplasmic Sox6
staining (Figure 1B, marked with * in Sox6
f/f). This obser-
vation may suggest an unknown additional mechanism to
relocate the Sox6 protein from the nucleus and/or
degrade it in differentiated, more mature myotubes. A
recent report on Six1/Six4 double KO muscle suggests
that these two proteins positively regulate fast-twitch
fiber differentiation and may also influence Sox6 nuclear
localization during fetal muscle development (E18.5)
[29]. In adult muscle, therefore, not only Sox6 expression,
but other mechanisms such as the Six1/Six4 regulated
Sox6 shuttling may be in place to finalize fiber type gene
expression in response to the environmental cues.
In addition to the muscle structural protein genes, we
also examined mRNA expression of the genes playing a
Table 1 Fold change in mRNA levels in the Sox6 KO skeletal muscles compared to control
TA EDL Gas Sol
Mouse age (month) 2 3 2 3232 3
Sox6 0.51 0.10 0.94 0.01 0.12 0.20 0.36 0.48
Myh7 (MyHC-b) 779.78 147.72 22.36 4186.18 5.75 11.24 1.80 2.71
Myh4 (MyHC-IIb) 0.03 3 × 10
-3 0.20 3 × 10
-3 0.12 2 × 10
-3 0.88 0.30
Ppargc1a (PGC1-a) 3.27 0.35 2.06 0.13 0.22 0.61 0.85 1.92
Sdha 1.02 0.38 1.93 0.68 0.97 0.51 1.00 1.27
Sox6 was inactivated using Myf5-Cre mice. A two month-old and a three month-old mice were examined. Control expression level = 1.00.
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Page 3 of 21Figure 1 The number of fibers expressing MyHC-b is dramatically increased in Sox6 KO skeletal muscle. A. Cross-sections of E18.5 lower
hindlimb muscle (TA-EDL region) from control (Sox6
f/f) and Sox6KO (Sox6
f/f; Myf5-Cre) were stained with DAPI (blue) or specific antibodies for
MyHC-b (green) or Sox6 (red). x400 magnification. B. P7 (7 day old) hindlimb muscle processed for DAPI, Sox6 and MyHC-b immune-staining.*
indicates myotubes that are negative for both MyHC-b and Sox6 staining in control muscle (see text for discussion). x400 magnification. C. Four
month old adult TA-EDL muscle. A control muscle section stained with DAPI or secondary antibodies (a mixture of both anti-mouse and anti-
rabbit) only was also shown. ×200 magnification.
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Sdha in adult muscle. Ppargca1 is a co-regulator of
mitochondrial biogenesis and oxidative phosphorylation
[30,31] and Sdha is a component of TCA cycle and
complex II of the mitochondrial respiratory chain,
w h o s ee x p r e s s i o ni sa c t i v a t e db yP p a r g c 1 a[ 3 0 ] .W e
speculated that Ppargca1 and Sdha mRNA expression
would also be upregulated in Sox6 KO muscle, because
of a correlation between oxidative metabolism and slow
fiber content reported in adult skeletal muscle [1,32,33].
In spite of this expectation, neither Ppargc1a nor Sdha
mRNA showed a noticeable increase in the Sox6 KO
muscles (Table 1). This lack of correlation of the two
gene programs was also observed in Sox6 KO muscles
generated using MCK-Cre transgenic mice (Table 2, dis-
cussed later in the text). In a recent report on the adult
Sox6 KO muscle phenotype, Quiat et al. also reported
that expression of Ppargc1a was not changed [34].
Therefore, these results suggest that Sox6 plays a role in
transcriptional regulation of the structural protein genes
which define muscle fiber types, but not of the genes
which define the metabolic state of skeletal muscle. In
order to uncover the mechanisms of muscle differentia-
tion that are regulated by Sox6 at the molecular level,
we next performed Sox6 ChIP-seq analysis.
Genome-wide Sox6 binding in skeletal myotubes
To identify genome-wide binding of Sox6 in mouse ske-
letal muscle, we performed ChIP-seq analysis. As the
chromatin source, we chose wild type fetal (E.18.5) myo-
tubes differentiated for 48 hours in vitro, because at this
time point, a significant differential expression of slow
fiber specific genes was observed between Sox6 null and
wild type myotubes [13], suggesting an ideal time point
to capture Sox6 acting as a transcriptional suppressor of
those genes. Also, since Sox6 is highly expressed in
fibroblasts (unpublished data), using a pure muscle cell
population was necessary to identify muscle-specific
Sox6 binding. We conducted two independent ChIP-seq
experiments and obtained 3 and 1.5 million reads unam-
biguously mapped to the mouse genome for each
experiment (out of ~20 million total reads). As a result,
Table 2 Fold change in mRNA levels in the Sox6 KO skeletal muscles compared to control
TA EDL Gas Sol
Mouse ID# 1 231231231 2 3
Sox6 0.75 0.42 0.09 0.43 0.38 0.07 0.38 0.53 0.10 0.20 0.31 0.12
Myh1 (IIx/d) 2.08 1.68 0.20 1.31 5.77 5.49 6.79 14.80 2.11 0.01 0.03 1 × 10
-3
Myh2 (IIa) 5.00 1.96 0.80 3.08 2.11 4.72 6.63 5.77 1.85 0.02 0.02 u.d.
Myh4 (IIb) 0.17 0.01 0.01 0.11 0.04 0.02 0.25 1 × 10
-3 0.02 0.16 0.16 0.01
Myh6 (a) 78.79 252.99 1.03 24.19 25.37 6.65 3.54 4.13 2.42 4.03 1.61 0.65
Myh7 (b) 9042.52 2177.81 94.12 1318.30 728.63 1611.29 21.86 3.59 9.68 3.60 1.00 1.20
Myh7b 31.37 n.d. 0.49 3.98 n.d. 1.39 14.30 n.d. 3.06 1.51 n.d. 0.34
Myl2 1496.57 n.d. 7.07 57.22 n.d. 55.59 7.37 n.d. 2.70 1.91 n.d. 1.31
Tnnc1 6830.19 4622.47 474.50 665.43 687.83 128.70 91.24 167.58 14.52 0.81 2.98 1.53
Tnni1 2619.20 1867.14 610.53 433.38 552.33 861.06 116.58 69.76 24.71 2.64 2.58 2.59
Tnni2 0.34 0.50 0.20 0.36 0.89 0.15 0.46 0.76 0.35 0.01 0.14 2 × 10
-3
Tnnt1 4348.43 1594.44 157.77 1011.39 510.51 153.18 131.98 59.18 5.07 2.93 1.76 1.56
Tnnt2 2.45 1.88 2.08 2.31 0.59 1.55 1.23 2.65 1.37 2.59 1.12 1.85
Tnnt3 0.45 0.40 0.43 0.28 0.89 0.58 0.34 0.38 0.19 4 × 10
-3 0.06 2 × 10
-4
Chrng (fetal) 0.89 4.63 4.94 0.73 1.80 1.82 1.23 1.80 3.29 2.78 1.17 8.26
Chrne (adult) 0.44 0.30 0.28 0.14 0.18 0.76 0.16 0.15 0.14 0.24 0.34 1.44
Prox1 29.26 10.30 9.66 22.84 6.68 17.04 16.21 8.41 3.34 3.79 2.26 1.27
Tead1 1.83 n.d. 0.99 0.63 n.d. 0.98 1.25 n.d. 0.78 1.02 n.d. 0.94
Tead4 3.03 n.d. 1.26 1.34 n.d. 1.08 1.23 n.d. 1.08 0.96 n.d. 1.11
Tcf4 1.94 n.d. 1.70 0.88 n.d. 1.54 1.68 n.d. 1.15 0.88 n.d. 1.43
Hdac9 4.44 n.d. 2.68 1.51 n.d. 1.79 7.56 n.d. 1.42 1.34 n.d. 0.75
Myod1 0.73 1.01 0.70 0.73 1.02 2.11 1.47 1.44 1.17 1.51 1.77 0.72
Myog 3.64 1.52 2.24 1.98 1.84 3.00 2.61 1.12 0.95 4.48 1.89 1.35
Mb 1.84 1.47 1.48 0.66 2.30 1.75 1.88 3.50 1.54 0.77 1.62 1.09
Sdha 1.18 0.74 0.39 0.70 0.74 0.50 0.79 0.60 0.32 0.68 0.59 0.55
Ppargc1a 1.28 1.39 0.53 0.82 0.78 0.35 0.63 1.46 0.42 0.53 0.71 0.19
Sox6 was inactivated using MCK-Cre mice. Mouse 1 and mouse 2 are two month-old, and mouse 3 is three month-old. Gene names in bold: associated with Sox6
binding. Gene names in italics: slow fiber specific sarcomere proteins, or transcription factors reported that are preferentially expressed in slow fibers. n.d.: not
determined. u.d.: undetected in Sox6 KO mouse. Control expression level = 1.00.
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ChIP-seq data sets. These peaks were assigned to a total
of 867 mouse RefSeq genes. The vast majority of the
Sox6 binding sites were located in intronic regions
(48.4%), followed by intergenic regions (more than 20
kb away from transcription start site (TSS) or transcript
end) (29.2%) and 5’-upstream region (within 20 kb of
TSS including promoter) (13.6%) (Figure 2).
To determine whether any known transcription factor
consensus sequences are over-represented within the
Sox6 peak regions, a motif search was performed. Motif
analysis using MEME (Multiple EM for Motif Elicita-
tion) [35] identified four known transcription factor
c o n s e n s u sm o t i f si nt h eS o x 6p e a k s( F i g u r e3 ) .W h e n
the occurrence of a single motif was set to 0 or 1 per
peak, 723 Sox motifs (P <1 0
-4) and 636 E-box motifs (P
<1 0
-4) were identified. The fact that the Sox consensus
motifs were found in the overwhelming majority of the
Sox6 peaks (723 out of 1,066) suggests that the Sox6
binding sites identified here are bona fide Sox6 targets.
The E-box motifs (CAG[C/G]TG) identified using the in
silico method here were identical to the E-box motifs
which were enriched in MyoD binding sites detected
using C2C12 myotubes [36]. Comparing our data with
the MyoD ChIP-seq data obtained from adult mouse
primary myotubes [36] revealed that 96% of the Sox6
peaks were localized within 50 bp of the MyoD peaks
(data not shown).
In addition to Sox motif and E-box, Runx and Tead/
MCAT motifs were also found in the Sox6 peaks. When
the occurrence of a single motif was set to 1, we identi-
fied 559 Runx motifs (P <1 0
-4)a n d2 0 3T e a d / M C A T
motifs (P <1 0
-4). A recent report has shown that Runx1
has a role in skeletal muscle terminal differentiation
[37]; therefore, Runx transcription factors might be
involved in muscle specific gene expression together
with Sox6. Tead/MCAT elements are known to play an
important role in transcriptional regulation of many ske-
letal and cardiac muscle-specific genes [38]. A signifi-
cant presence of Tead/MCAT motifs in the Sox6 peaks,
therefore, implies possible interactions between Sox6
Figure 2 Genome-wide mapping of Sox6 binding sites by ChIP-seq. Locations of Sox6 binding sites relative to the nearest RefSeq genes
and the percentages of binding sites at the respective locations are shown.
Figure 3 Transcription factor consensus motifs found in Sox6
binding peaks.
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differentiation.
Transcriptional status of the genes associated with Sox6
binding sites
In order to determine the transcriptional status of Sox6
peak-associated genes in differentiating fetal myotubes,
w ep e r f o r m e dC h I P - s e qa n a lysis using an antibody
recognizing a phosphorylated form of Pol II, which is
considered to be a transcriptionally active form and asso-
ciated with highly transcribed genes [39]. To quantify Pol
II binding levels of RefSeq genes associated with Sox6
binding sites, Pol II binding events in the corresponding
gene regions were measured in RPKM (reads per kilobase
of gene region per million reads), a unit used to quantify
transcriptional levels in RNA-seq analysis [40]. RPKM
was calculated from read (tag) numbers in peak regions,
length of RefSeq gene regions, and total number of
uniquely mapped reads (details in Methods). By this
method, the Pol II binding level of the b-actin gene, an
abundantly expressed housekeeping gene, was calculated
as 8.60 RPKM. Figure 4 summarizes the fold enrichment
of the Sox6 peaks and the corresponding Pol II binding
of the 867 RefSeq genes associated with Sox6 peaks. We
found that the majority of the Sox6 binding site(s)-asso-
ciated genes were inferred to be transcriptionally inactive
(zero to a very low level of Pol II binding). As shown in
Figure 4 andAdditional file 2, Table S1, of the 867 genes
associated with Sox6 binding sites, 442 genes (51%)
showed no Pol II binding (0 RPKM) and 289 genes (33%)
showed less than one tenth of the Pol II binding to the b-
actin gene (<0.86 RPKM), thus 84% of the genes asso-
ciated with Sox6 binding sites are considered to be tran-
scriptionally inactive or transcribed at a very low level in
myotubes. These data strongly suggest that the binding
of Sox6 to its targets mostly results in transcriptional
suppression. The rest of the Sox6 peak associated genes
were transcribed mostly at a range of low to moderate
levels (less than half of the Pol II binding to the b-actin
gene). There were, however, a small number of Sox6
peak-associated genes that exhibited a high level of Pol II
binding. For example, Myl4 (embryonic MyLC isoform),
Tnnc1,a n dMyh3 (embryonic MyHC isoform) showed a
relatively high level of Pol II binding (>4.30 RPKM). In
the case of Tnnc1, one of the two Sox6 peaks was identi-
fied in the first intron (Additional file 3, Figure S2D),
where a muscle enhancer element was reported [41].
Therefore, an unidentified enhancer element may exist in
the vicinity of the Sox6 binding sites in Myl4 and Myh3.
Functional characterization of the genes associated with
Sox6 binding sites
Gene Ontology (GO) analysis revealed that the Sox6
peak-associated genes showed the highest enrichment
for the GO categories relevant to muscle cytoskeleton
and myofibril establishment (Table 3). Many of these
Figure 4 Comparison of Sox6 binding and Pol II binding to the Sox6 target genes. Left Y axis shows fold enrichment of Sox6 obtained by
the peak calling program SISSRs using the 3 million read data set (see the text for detail), and right Y axis shows Pol II binding levels to the
Sox6 peak-associated genes measured in RPKM. X axis shows all Sox6-associated genes (867 RefSeq genes in total) sorted according to Pol II
binding and chromosomal location. When multiple Sox6 peaks were associated with one gene, only the peak with the highest fold enrichment
was used. Note that Pol II binding to b-actin, an abundantly expressed housekeeping gene, was 8.60 RPKM. A similar result was obtained using
the 1.5 million read-data set (data not shown).
An et al. BMC Developmental Biology 2011, 11:59
http://www.biomedcentral.com/1471-213X/11/59
Page 7 of 21genes encode muscle sarcomeric proteins which define
fiber types, cardiac isoforms, and developmental iso-
forms in muscle. For instance, Myh1 (fast MyHC-IIx/d),
Myh2 (fast MyHC-IIa), Myh6 (cardiac isoform, MyHC-
a), Myh7 (slow MyHC-b), Myh7b (myosin, heavy chain
7B, cardiac muscle, beta), Tnnc1 (troponin C, cardiac/
slow skeletal), and Tnni1 (troponin I, skeletal, slow 1)
were represented. The profiles of Sox6 binding and Pol
II binding for these genes are summarized in Additional
file 3, Figure S2A-E. Except for Tnnc1 (4.72 RPKM) and
Tnni1 (3.52 RPKM), Pol II binding levels of these genes
were very low (Additional file 3, Figure S2A-E). It
should be noted that Sox6 peaks were not detected for
Myh4 (Additional file 3, Figure S2A) which encodes the
fastest adult myosin isoform MyHC-IIb [2,3] nor for
Myh8 (data not shown) which encodes the perinatal fast
MyHC isoform [5]. This suggests that Sox6 is not
directly involved in transcriptional regulation of the
fastest MyHC isoforms expressed in fetal or adult skele-
tal muscle.
Another noticeable GO term category enriched in the
genes associated with Sox6 peaks involved regulation of
transcription (Table 3). For instance, Sox6 peaks were
found in the vicinity or in the gene region of transcriptional
regulators including (but not limited to) Prox1, Sox6,
Tead1, Tead4, Tcf4, Hdac9, Hdac11,a n dNfatc3 (Addi-
tional file 3, Figure S2F-M). These genes (except for
Hdac11) are known to play a role in not only skeletal mus-
cle development, but also heart development
[12,13,38,42-49]. In spite of its high expression in skeletal
muscle, the role of the class IV histone deacetylase Hdac11
[50] in muscle development is yet to be discovered [51].
Prox1 encodes a transcription factor expressed in slow
muscle in zebrafish [47]. Though its role in mammalian
skeletal muscle development is yet to be reported, we
hypothesize that the Prox1 protein also plays a role in
Table 3 Biological processes enriched among genes associated with Sox6 peaks
GO term P value
GO:0015629~actin cytoskeleton 2.58E-013







GO:0045944~positive regulation of transcription from RNA polymerase II promoter 1.40E-006
GO:0045893~positive regulation of transcription, DNA-dependent 2.93E-006
GO:0051254~positive regulation of RNA metabolic process 3.50E-006
GO:0007517~muscle organ development 5.48E-006
GO:0030017~sarcomere 5.82E-006
GO:0043228~non-membrane-bounded organelle 6.45E-006
GO:0043232~intracellular non-membrane-bounded organelle 6.45E-006
GO:0006357~regulation of transcription from RNA polymerase II promoter 7.81E-006
GO:0007010~cytoskeleton organization 8.98E-006
GO:0010628~positive regulation of gene expression 1.05E-005
GO:0045941~positive regulation of transcription 1.25E-005
GO:0045935~positive regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolic process 1.37E-005
GO:0044449~contractile fiber part 1.39E-005
GO:0010557~positive regulation of macromolecule biosynthetic process 1.59E-005
GO:0060537~muscle tissue development 1.77E-005
GO:0031328~positive regulation of cellular biosynthetic process 2.01E-005
GO:0009891~positive regulation of biosynthetic process 2.50E-005
GO:0007507~heart development 2.69E-005
GO:0048729~tissue morphogenesis 2.78E-005
GO:0051173~positive regulation of nitrogen compound metabolic process 2.88E-005
GO:0042692~muscle cell differentiation 3.41E-005
GO:0006936~muscle contraction 3.79E-005
The thirty most enriched Gene Ontology (GO) biological process terms are listed.
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t h i s ,w eh a v ef o u n dt h a tP r ox1 mRNA is preferentially
expressed in the slow soleus muscle compared to the
EDL, TA, and gastrocnemius muscles in adult (Addi-
tional file 1, Figure S1B). Therefore, the Prox1 protein
may play a role in slow fiber differentiation during mus-
cle development as well as maintenance of slow muscle
in adult. In the Sox6 gene region, two Sox6 peaks were
detected in the fifth intron (Additional file 3, Figure
S2G). Existence of Sox6 binding sites and very low levels
of Pol II binding in the Sox6 gene region may suggest a
self-regulatory mechanism of Sox6 transcription during
skeletal muscle development, as has been recently
reported for erythrocyte development [52].
We also examined whether Tead1, Tead4, Tcf4,
Hdac9 and Hdac11 are differentially expressed between
slow and fast muscles. We found that Tead1, Tead4,
Tcf4 and Hdac9 were all expressed higher in the slow
soleus muscle than the group of fast muscles, EDL, TA,
and gastrocnemius (Additional file 1, Figure S1C-F).
Hdac11, on the other hand, was expressed slightly
higher in the fast muscles than soleus (Additional file 1,
Figure S1G). These results suggest that Tead1, Tead4,
Tcf4 and Hdac9 may also positively regulate slow fiber
specific genes. The association of Sox6 peaks to these
transcriptional regulatory genes suggests that Sox6 may
be indirectly regulating muscle development through
these key transcription regulators.
Sox6 binding to the genes described above was vali-
dated by ChIP-qPCR (Additional file 4, Figure S3).
Muscle specific inactivation of Sox6 results in significant
upregulation of slow fiber, cardiac, and developmental
isoform genes in skeletal muscle
The observation that the majority (84%) of the genes
associated with Sox6 binding sites show little or no Pol
II binding (Figure 4) supports our hypothesis that a
major function of Sox6 during myogenesis is transcrip-
tional suppression. To further evaluate this hypothesis,
we next analyzed mRNA expression of selected genes
associated with Sox6 binding in Sox6 KO muscle. For
this, we used MCK-Cre mice (harboring the Cre gene
under the control of the muscle creatin kinase promo-
ter) to assess the effect of Sox6 inactivation in skeletal
muscle as well as in cardiac muscle [53,54], since many
of the putative Sox6 target genes are also expressed in
the heart.
First, mRNA levels of the eighteen genes (eight fiber
type-specific genes, two cardiac isoform genes, one
developmental isoform gene and five transcription fac-
tors and two histone modification enzyme genes) were
compared between control and Sox6 KO mice using
newborn skeletal muscle (Figure 5). Sixteen genes out of
the eighteen tested showed a significant increase in
mRNA expression in the newborn Sox6 KO skeletal
muscle (Figure 5). Nfatc3 and Hdac11 showed a
Figure 5 Differences of expression levels of Sox6 target genes between control and Sox6 KO perinatal mice. RT-qPCR was performed
using total RNA from skeletal muscle of control (Sox6
f/f) and Sox6 KO (Sox6
f/f; MCK-Cre) newborn (postnatal day 1) mice. Expression levels in
Sox6 KO mice were divided by those in control mice, and represented as mean ± SD (n = 3). The broken line corresponds to the expression
ratio of 1, indicating equal expression level between the KO and control mice. (*) P < 0.05; (**) P < 0.005. Fiber type specific genes: Myh1, Myh2,
Myh7, My7b, Myl2 (also expressed in the heart), Tnnc1 (also expressed in the heart), Tnni1, Tnnt1; cardiac isoforms: Myh6, Tnnt2; developmental
isoform: Myl4; transcription factors: Prox1, Tcf4, Tead1, Tead4, Nfatc3; histone modification enzymes: Hdac9, Hdac11.
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though the difference was not statistically significant
(Figure 5). These results indicate that Sox6 functions as
a suppressor for these genes in developing muscle.
Next, we assessed mRNA expression of fifteen genes
out of the eighteen tested above (Myl4, Nfatc3,a n d
Hdac11 were excluded) as well as fast fiber specific
genes, myogenic regulatory factors, and metabolism
related genes in adult Sox6 KO muscle (Table 2). The
slow fiber specific sarcomeric protein genes which had
shown increased expression in Sox6 KO newborn mus-
cle (Myh7, Myl2, Tnnc1, Tnni1, and Tnnt1) displayed an
even greater fold increase in mRNA expression in adult
Sox6 KO muscles compared to control (Table 2).
Among the four muscle groups tested, the TA and EDL
Sox6 KO muscles showed the most dramatic increase in
slow fiber specific gene expression, the soleus exhibiting
the least fold increase (Table 2), again likely reflecting
the lower Sox6 expression in the soleus than the fast
muscles TA, EDL, and gastrocnemius (Additional file 1,
Figure S1A). The fast fiber specific genes (Myh4, Tnni2,
and Tnnt3) exhibited a significant decrease in their
mRNA expression in Sox6 KO muscles (Table 2). Myh1
(IIx/d) and Myh2 (IIa), were either increased or
decreased in different Sox6 KO muscle groups (Table
2), which may reflect the fluid nature of MyHCs IIa and
IIx/d’s expression in adult skeletal muscle [2]. These
two MyHC isoforms are intermediates between MyHC-
b and MyHC-IIb when fiber type shift occurs in skeletal
m u s c l e .T h e r e f o r e ,t h e yc o u ld be more sensitive to the
timing and level of the Sox6 gene inactivation, leading
to varied expression in the individual Sox6 KO muscles.
Upregulation of the cardiac isoform genes, Myh6 and
Tnnt2, was also observed in the adult Sox6 KO muscle
(Table 2).
The significant upregulation in the slow fiber and cardiac
isoform gene expression in adult Sox6 KO skeletal muscle
likely suggests that inactivation of the Sox6 gene early in
myogenic development inhibited the postnatal maturation
of the skeletal muscle. Postnatal development of skeletal
muscle is characterized by the progressive decline of slow
fiber specific gene expression in fast muscles [6,7,55]. As a
result, control EDL and TA muscles express only a trace
amount of the MyHC-b protein [6,56,57]. The extreme
upregulation of the slow fiber specific genes such as Myh7,
Tnnc1,a n dTnnt1 in the Sox6 KO fast muscles may reflect
their suspended postnatal maturation. This delayed
maturation hypothesis is supported by the observation that
the embryonic isoform acetylcholine receptor (Ach-R) g
(Chrng) is expressed at a higher level than the adult iso-
form Ach-R ε (Chrne) in Sox6 KO muscles (Table 2). Dur-
ing postnatal maturation of skeletal muscle, Ach-R g is
replaced by the adult isoform Ach-R ε [58]. In the adult
Sox6 KO muscles, silencing of Chrng was not seen and
Chrne expression did not reach to the control level (Table
2). Since we have located one Sox6 peak in the Chrng pro-
moter region (approximately 135 bp upstream of the TSS),
Sox6 may be directly suppressing transcription of Chrng
during normal skeletal muscle development.
Transcriptional regulatory genes associated with Sox6
peaks are upregulated in Sox6 KO adult muscle
In addition to the sarcomeric protein genes, mRNA
levels of some of the transcriptional regulatory genes
associated with Sox6 peaks were upregulated in the
Sox6 adult KO skeletal muscles. Prox1 expression was
significantly increased in Sox6 KO muscles, with the
highest fold increase in the TA and EDL, followed by
the gastrocnemius (Table 2). It should be noted that
Prox1 expression is highest in the soleus in the adult
control (Sox6
f/f) muscles (Additional file 1, Figure S1B).
These observations suggest that Prox1 m a yp l a yar o l e
for sustaining slow fiber specific gene expression in
adult muscle. Tead4 and Hdac9 also showed a slight
increase in their expression in the Sox6 KO TA, EDL,
and gastrocnemius muscles (Table 2). Expression of
Tcf4 and Tead1, on the other hand, showed no clear dif-
ference between Sox6 KO and control adult muscles
(Table 2), in spite of their higher expression in the Sox6
KO newborn muscle (Figure 5). This result suggests that
Sox6 may regulate transcription of Tcf4 and Tead1 in
developing muscle, but this regulation may not be main-
tained through adult.
Since it has previously been reported that MyoD and
Myogenin are differentially expressed between slow and
fast muscles (MyoD higher in fast than slow; Myogenin
higher in slow than fast) [59,60], we also examined
mRNA expression of these genes in Sox6 KO muscle.
As shown in Table 2, there was no discernable change
in MyoD mRNA expression, whereas there was a small
increase in Myogenin mRNA expression in Sox6 KO
muscles. An increase in Myogenin expression in Sox6
KO muscle suggests that Myogenin may play some role
in maintaining slow fiber phenotype in the adult skeletal
muscle as previously proposed [60].
The level of transcriptional upregulation of metabolism
related genes is less than that of slow fiber sarcomere
protein genes in Sox6 KO muscle
Since a close coupling between the slow fiber gene pro-
gram and the oxidative metabolism gene program in
adult skeletal muscle has been reported [1,3], we also
examined mRNA expression of the genes whose high
expression is correlated with the oxidative state of skele-
tal muscle metabolism in Sox6 KO muscle (myoglobin,
Sdha and Ppargc1a). In MCK-Cre induced Sox6 KO
muscle, mRNA levels of Ppargc1a and Sdha were, in
general, lower than control (Table 2). These results
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Sox6 KO muscle (Table 1). Myoglobin expression
showed a slight increase in the Sox6 KO TA, EDL, and
gastrocnemius (Table 2). When the color of gastrocne-
mius and soleus muscles was visually inspected, the
characteristic color difference between the two muscles
in control muscle (soleus being redder than gastrocne-
mius) was less clear in Sox6 KO muscle, because the
Sox6 KO gastrocnemius exhibited an increase in redness
in its color (Figure 6). This may reflect a small, but con-
sistent increase in myoglobin expression in the Sox6 KO
g a s t r o c n e m i u sm u s c l e( T a b l e2 ) .T h em o r er e dm u s c l e
in Sox6 KO muscle has been also reported by Quiat et
al. [34]. Interestingly, both Quiat et al. and our current
report observed reduced expression in Ppargc1a in Sox6
KO muscle, which may suggest that there could be a
pathway independent of Ppargc1a regulating myoglobin
expression in Sox6 KO muscle. An alternative explana-
tion for the increased redness in the Sox6 KO muscle
c o u l db eac h a n g ei nc a p i l l a r yd e n s i t y .I nt h eS o x 6p e a k
associated RefSeq genes, GO terms related to vascula-
ture development and angiogenesis were also enriched
(P <2×1 0
-3) (Additional file 5, Table S2). Thus, the
increased capillary density could be the cause of more
red color of the Sox6 KO gastrocnemius.
Fetal isoform gene expression is upregulated in the Sox6
KO heart
Since the two cardiac MyHC isoform genes, a and b
(Myh6 and Myh7), were associated with Sox6 binding
(Additional file 3, Figure S2B) and their expression was
upregulated in Sox6 KO skeletal muscle (Figure 5, Table
2 ) ,w en e x te x a m i n e dt h e i re x p r e s s i o ni nt h eS o x 6K O
heart. In the mouse heart, expression of MyHC-a and
MyHC-b is developmentally regulated. MyHC-b is the
fetal isoform in the heart and is replaced by the adult
isoform MyHC-a within the first week after birth [61].
As summarized in Table 4 it appears that this isoform
transition, fetal to adult, is incomplete in the Sox6 KO
myocardium. In the Sox6 KO heart, MyHC-b expression
was sustained at an equal to a slightly higher level than
control heart, whereas MyHC-a expression decreased to
approximately the half of the control level (Table 4). To
test if this is a developmental defect in the postnatal
heart, we also examined expression of the developmen-
tally regulated skeletal a-actin gene, which is expressed
in the fetal heart and silenced later in adult [62]. Indeed,
skeletal a-actin mRNA expression was consistently
higher in the Sox6 KO heart (Table 4), suggesting that
the Sox6 KO heart is developmentally more immature
than the control heart. Interestingly, the expression of
Ppargc1 was also lower in the Sox6 KO heart (Table 4).
Since Ppargc1 plays an important role in maturation of
the metabolic state and mitochondrial biogenesis in the
postnatal heart [63-65], this result suggests that the loss
of Sox6 caused a delay in the postnatal maturation of
the heart, thus Sox6 may also be necessary for the func-
tional maturation of cardiac muscle.
Nfatc3 protein expression is highly upregulated in Sox6
null myotube cultures
It has been reported that Nfatc3 stimulates myogenic
differentiation both in vivo and in vitro [43,45]; how-
ever, its implication in muscle fiber type specification
has not been noted. Calcineurin-directed dephosphoryla-
tion of NFAT factors results in their nuclear localization
and transcriptional activation of their target genes [66].
We have located one Sox6 peak in the last intron of
Nfatc3 (Additional file 3, Figure S2J). As shown in Fig-
ure 5, Sox6 KO newborn skeletal muscle showed a
small increase (not statistically significant) in Nfatc3
mRNA expression. To assess whether the Nfatc3 activity
increases in Sox6 null myotubes, we examined sub-cel-
lular localization the Nfatc3 protein using Western blot.
We took advantage of the Sox6 null mouse (p
100H-Sox6
null mutant allele) in our laboratory to obtain a pure
population of Sox6 null myotubes [12,13,26]. Fetal
Table 4 Fold change in mRNA levels in the Sox6 KO heart
compared to control
Heart
Mouse ID# 1 2 3
Sox6 0.23 0.16 0.30
Myh6 0.67 0.61 0.51
Myh7 3.40 1.78 1.25
Acta1 (sk-actin) 4.28 4.36 2.55
Ppargc1a 0.52 0.57 0.51
Sox6 was inactivated using MCK-Cre mice. Mouse 1 and mouse 2 are two
month-old, and mouse 3 is three month-old. Control expression level = 1.00.
Figure 6 Morphological difference of skeletal muscle between
control and Sox6 KO mice. Dissected gastrocnemius/soleus
muscles from three month old mice are shown. A. control (Sox6
f/f)
muscle. B. Sox6 KO (Sox6
f/f; MCK-Cre) muscle.
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100H-Sox6 null
and wild type littermates and were differentiated in dif-
ferentiation medium (DM). In undifferentiated myoblast
cultures, the amount of the nuclear as well as cytoplas-
mic Nfatc3 protein was comparable between Sox6 null
and wild type (Figure 7). Once myotube differentiation
was induced, in wild type cultures, the Nfatc3 protein
was detected only in the nuclear fraction, whereas in the
p
100H cultures, a continuous presence of the cytoplasmic
Nfatc3 protein and a higher level of the nuclear Nfatc3
protein (compared to wild type) were observed (Figure
7). We have previously reported that Sox6 expression is
significantly increased upon induction of myotube differ-
entiation [13]. Therefore, these results suggest that a
higher level of Sox6 expression in wild type myotubes
likely suppressed new synthesis of Nfatc3, while the
absence of Sox6 in p
100H myotubes allowed continuous
Nfatc3 synthesis. These results suggest that Nfatc3 activ-
ity is upregulated in the Sox6 null myotubes which show
a higher level of slow fiber specific gene expression.
Functional analysis of the Sox6 binding sites
In order to characterize the functional nature of the
Sox6 binding sites in transcriptional regulation, we next
performed reporter gene assays. We chose five Sox6
peak-associated genes, Myh7 (MyHC-b), Myh7b, Tnnc1,
Tnni1and Hdac11, in which Sox6 binding was validated
by ChIP-qPCR (Additional file 4, Figure S3). All of these
Sox6 peaks tested contained a Sox consensus motif.
Firefly luciferase vectors containing each of the follow-
ing sequences, ~3.5 kb Myh75 ’-upstream sequence (two
Sox6 peaks; MHC3500), ~6 kb Myh7b 5’-upstearm
sequence (one Sox6 peak), ~1.3 kb of the Tnnc1 first
intron (one Sox6 peak), ~5.2 kb Tnni1 5’-upstream
region (two Sox6 peaks), and ~1 kb Hdac11 5’-upstream
sequence (one Sox6 peak) were generated (Figure 8A;
see Additional file 3, Figure S2B-E and S2M for the
location of Sox6 peaks). It should be noted that the
proximal Sox6 peak in the Tnni1 5’-upstream region
(approximately -800 bp from TSS) overlapped with the
previously reported slow upstream regulatory element
(SURE) containing an enhancer element [67].
To assess whether these Sox6 binding sites function as
a negative or positive regulatory element, the luciferase
reporter gene constructs described above were transi-
ently transfected to p
100H-Sox6 null and wild type myo-
blasts, differentiated in DM for 48 hours, after which
firefly luciferase activities were compared between the
Sox6 null and wild type myotube cultures. If these Sox6
binding sequences function as negative regulatory
regions, it is expected that the luciferase activity would
be higher in p
100H myotube cultures in which no func-
tional Sox6 protein is produced. As summarized in Fig-
ure 8B, four out of the five sequences tested drove a
higher firefly luciferase activity in Sox6 null myotube
cultures compared to wild type, indicating that these
Sox6 binding sites function as negative regulatory
sequences. The Myh7b 5’- s e q u e n c ed i dn o td r i v eas t a -
tistically higher luciferase activity in Sox6 null myotube
cultures (Figure 8B). Since the endogenous Myh7b
expression was higher in Sox6K Om u s c l e( F i g u r e5 ) ,i t
is possible that the in vitro culture may not be the best
approach to assess the effect of the Myh7b Sox6 biding
regions. Intriguingly, Bell et al. have shown that Sox6
protein overexpression in C2C12 cells could suppress
transcription from the 1 kb Myh7b 5’-upstream
sequence [68]. Therefore, there could be a Sox6 binding
site not detected in our ChIP-seq analysis which may
still be functioning as a negative regulatory element in a
different context.
We have previously shown that the proximal Sox6
binding site (-200 bp from the Myh7 TSS) functions as
an e g a t i v er e g u l a t o r ye l e m e n ti nr e p o r t e rg e n ea s s a y s
[13]. In the present report, we have identified an addi-
tional distal Sox6 binding site (-2900 bp from TSS)
which overlaps with a known muscle enhancer element
[69,70]. To delineate the two Sox6 binding sites in the
Myh7 5’-upstrem region (see Additional file 3, Figure
S2B for the peak locations), the distal Sox consensus
sequence (-2,900 bp) was mutated in MHCb3500 (desig-
nated as MHC b3500 m) (Figure 8A). As shown in
Figure 7 Nfatc3 protein levels are increased in both the
nucleus and cytoplasm of Sox6-null myotubes. Wild type (WT)
and Sox6-null (p
100H) fetal primary myoblasts or myotubes were
harvested at 0, 24, 48, 72, and 96 h after switching to DM, and
nuclear and cytoplasmic protein was extracted for Nfatc3 Western
blotting. TATA binding protein (TBP) and tubulin were used as
loading controls for nuclear and cytoplasmic fractions, respectively.
Upper panels: nuclear fractions. Lower panels: cytoplasmic fractions.
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the luciferase activity in either Sox6 null or wild type
myotubes. This result suggests that the distal Sox motif
has little effect on transcriptional suppression from the
3.5 kb Myh7 5’-region in transient assays, and therefore,
at least in the current in vitro assay conditions, the
proximal Sox6 binding site is sufficient to suppress the
transcription driven by the 3.5 kb Myh7 5’-upstream
region.
The function of the Sox6 binding site in the Tnnc1
first intron was determined using a hybrid luciferase
reporter construct whose transcription is driven by the
chicken b-actin promoter. The Tnnc1 first intron con-
tains an enhancer element which was previously identi-
fied using C2C12 and Sol8 skeletal muscle cell lines
[41]. The presence of this intron alone significantly
increased luciferase activity in wild type myotubes
(Actb-p vs. Actb-p+Tnnc1, p < 0.0001), confirming the
enhancer activity (Figure 8B). The luciferase activity of
the construct, Actb-p+Tnnc1, in Sox6 null myotubes
was significantly higher than wild type, indicating that
Sox6 binding hindered the enhancer activity in this
intron (Figure 8B). Unexpectedly, the construct contain-
ing only the chicken b-actin promoter exhibited a small
but statistically significant increase in luciferase activity
in Sox6 null myotube cultures compared to wild type
(Figure 8B). This was likely caused by the fortuitous pre-
sence of a couple of Sox motif sequences in the chicken
b-actin promoter and intron sequences in the vector
(data not shown), which could have functioned as a
weak silencer element. The 5’-upstream sequences of
both Tnni1 and Hdac11 showed a moderate but statisti-
cally significant increase in luciferase activity in Sox6
null myotubes (Figure 8).
Discussion
In order to understand how Sox6 regulates muscle dif-
ferentiation at the molecular level, we have performed
ChIP-seq analysis to identify Sox6 targets in skeletal
myotubes and extended the characterization of the Sox6
null muscle phenotype using muscle specific Sox6 inac-
tivation. Among the 867 Refseq genes found to be asso-
ciated with Sox6 peaks, the overrepresented GO terms
included muscle structure and function, skeletal muscle
and heart development, as well as transcriptional regula-
tion. In a concurrently conducted Pol II ChIP-seq analy-
sis, we found that the majority of the Sox6 peak-
associated genes exhibited little to no recognizable bind-
ing peaks, suggesting that Sox6 mainly functions as a
transcription suppressor in developing muscle.
How does Sox6 suppress its target genes? Based on
evidence from this and other labs, we can speculate on
two possible mechanisms (1a n d2 )a n d ,b a s e do ne v i -
dence accumulated in this report we also demonstrate
two other likely mechanisms (3 and 4): (1) Sox6 may
fine-tune the transcription of the genes that have been
marked by MyoD binding, (2) Sox6 may modulate tran-
scription of its target genes in concert with Tead and
Runx factors, (3) Sox6 suppresses transcription by hin-
dering the muscle-specific enhancer activity, and (4)
Sox6 also indirectly influences downstream gene expres-
sion by regulating the expression of other transcription
Figure 8 Differences of reporter activities between wild type and Sox6-null primary myotubes. A. Schematic representations of the firefly
luciferase vectors constructed to test the function of Sox6 binding sequences. Black boxes indicate the firefly luciferase gene and shaded boxes
indicate the chicken b-actin promoter (Actb-p). Open boxes indicate the upstream sequences of the wild type MyHC-b gene (MHCb3500) or its
mutated version (MHCb3500 m; cross indicates mutation), Myh7b, Tnni1, and Hdac11, or the first intron sequence of Tnnc1. Approximate
positions of Sox6 binding sites are indicated by gray lines. B. The reporter constructs shown in A were cotransfected with a Renilla luciferase
vector into wild type (WT) and Sox6-null (p
100H) primary myoblasts. After differentiation into myotubes, both luciferase activities were measured
and normalized with Renilla luciferase activity. Data were further normalized to WT MHCb3500 value (i.e. MHCb3500 in WT = 1.0), and
represented as mean ± SD (n = 3). (*) P < 0.05; (**) P < 0.005.
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will discuss each of these proposed mechanisms in more
detail.
MyoD is one of the myogenic regulatory factors and
defines the myogenic lineage during development
[71,72]. In myotubes, MyoD binding events are frequent
(~26,000 peaks with a higher cut off, ~60,000 peaks
with a lower cut off) and are associated with histone H4
acetylation (H4Ac) [36], which is a marker of an active
chromatin state [73]. We found that 96% of the Sox6
peaks in fetal myotubes overlapped with, or were in the
close vicinity to (within 50 bp), the reported MyoD
peaks [34]. The E-box motifs in the Sox6 peak regions
we found were enriched for the CAGCTG E-box
sequence (Figure 3). Previously, it has been shown that
this motif is represented in the peaks more strongly
bound in C2C12 myotubes compared to myoblasts, indi-
cating that this E-box motif is mainly associated with
the genes regulating muscle differentiation [36]. Taking
this observation together with ours, we speculate that
MyoD binding in the myotube would change the chro-
matin environment in such a way as to allow the
approach of additional transcriptional regulators by
recruiting the chromatin modifying enzymes [74], thus
allowing the fine-tuning of muscle specific gene expres-
sion necessary for the formation of mature skeletal mus-
cle. Sox6 could be one of these additional
transcriptional regulators and specify fiber type charac-
teristics during muscle terminal differentiation.
We have previously reported that Sox6 interferes with
a MCAT enhancer located in close proximity to the Sox
consensus motif in Myh7, causing suppression of Myh7
transcription [13]. Tead/MCAT motifs are frequently
found in enhancer or promoter regions of muscle speci-
fic genes and it has been demonstrated that binding of
TEF-1/Tead1 to the MCAT motifs activates transcrip-
tion of these muscle-specific genes [38,75]. In our analy-
sis of the 1,066 Sox6 peaks, we found 203 MCAT
motifs. This suggests that the mechanism of Myh7 tran-
scriptional suppression by Sox6 (possibly via physical
interference) we reported earlier may be a common
mechanism Sox6 uses to suppress genes whose tran-
scription is activated via Tead/MCAT motifs. Our analy-
sis also revealed 559 Runx motifs in the 1,066 Sox6
peaks. Currently, the roles of Runx motif binding factors
(Runx-1, -2, and 3) in muscle development are not well
known, though there are reports showing that Runx1
plays a role in skeletal muscle differentiation [37,76,77].
In adult skeletal muscle, Runx1 expression is induced by
denervation [77], and muscle-specific Runx1 inactivation
leads to accelerated muscle wasting in denervated mus-
cle [76]. In an earlier stage of muscle differentiation, it
has been reported that Runx1 directly interacts with
MyoD preferentially in proliferating myoblasts to inhibit
terminal differentiation of skeletal muscle [37]. The
a u t h o r ss h o w e dt h a tt h eR u n x 1 / C B F b complex recruits
suppressive chromatin modifying enzymes (e.g. HDACs),
thus inactivating transcription of the MyoD target genes
that are necessary for the cell cycle exit and differentia-
tion [37]. Since the Runx proteins have been shown to
function as transcriptional suppressors or activators in
different circumstances [78] (similar to Sox6), the tran-
scriptional outcome of the possible interaction between
the Sox6 and Runx proteins needs further investigation.
As demonstrated in the Results section, the Sox6
binding sites in the Tnnc1 first intron and the Tnni15 ’-
upstream region both effectively reduced the activity of
the enhancer elements (Figure 8). The molecular
mechanisms by which Sox6 overrides muscle enhancers
is currently under investigation; however, the skeletal
muscle MyHC gene clusters may help shed light on this
role of Sox6. In the six MyHC isoform genes clustered
on the mouse chromosome 11 [Myh3 (emb), Myh2 (IIa),
Myh1 (IIx/d), Myh4 (IIb), Myh8 (peri), Myh13 (eo)] [74],
only the Myh4 and Myh8 genes were not associated
with Sox6 peaks (a Sox6 peak was detected in the 5’-
upstream region of Myh13 in one of the two ChIP-seq
d a t as e t s ;d a t an o ts h o w n ) .T h e r e f o r e ,S o x 6m a yb e
involved in sequential expression of the MyHC loci, pos-
sibly in collaboration with an enhancer element similar
to the locus control region (LCR) reported for the glo-
bin gene cluster [79]. This is an appealing hypothesis,
because it has been shown that Sox6 (acting as a tran-
scriptional suppressor) regulates sequential expression of
the b-globin genes during erythrogenesis [80] in concert
with BCL11A which binds to the globin gene LCR [81].
There have been reports on transcription factories that
unite transcriptionally active genes on separate chromo-
some regions for coordinated transcription [82]. It is
possible that association of Sox6 with its target
sequences inhibits transcriptional initiation by Pol II,
thus causing dissociation of Sox6 target genes from
transcription factories.
We demonstrated that expression of Tead1, Tead4,
Hdac9,a n dProx1 was upregulated in Sox6 KO skeletal
muscle (Figure 5), suggesting that Sox6 is a suppressor
of these transcriptional regulatory genes. Tead1 (TEF-1)
and Tead4 (RTEF-1) are highly expressed in muscle tis-
sues and have been reported to activate muscle specific
gene transcription [83-85]. Hdac9 is a class IIa HDAC
[86] and functions as a mediator of motor neuron input
to skeletal muscle [87]. Prox1 is expressed in slow mus-
cle in zebrafish [47]. Since Prox1 is preferentially
expressed in slow fiber muscle in control mice (Addi-
tional file 1, Figure S1B) and Sox6 inactivation caused a
sizable increase in Prox1 mRNA expression in Sox6 KO
muscle, we propose that Prox1 also plays a role in regu-
lation of slow muscle fiber specific gene expression in
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lutionary conservation in the mechanisms regulating
muscle fiber type differentiation in vertebrates [19,88].
Since there are more transcriptional regulator genes that
are closely associated with Sox6 peaks, which we did
not have space to discuss in this report, it is likely that
Sox6 is part of the transcriptional networks that shape
the characteristics of both muscle development and
mature muscle functions.
The most striking phenotype of Sox6 null skeletal
muscle is the dramatic increase in the expression of
multiple slow fiber specific genes. This observation ori-
ginally led us to hypothesize that Sox6 functions as a
transcriptional suppressor of slow fiber specific genes
[12,13]. In this report, we expanded the gene expression
profiling of Sox6 KO skeletal muscle by including car-
diac and embryonic muscle isoform genes. Cardiac iso-
forms Myh6 and Tnnt2, as well as embryonic isoforms
Myl4 and Chrng, were upregulated in the Sox6 KO mus-
cle (Figure 5, Table 2). It has been reported that Tnnt2
is upregulated in regenerating dystrophic muscle [89].
Myh6 is expressed in specialized craniofacial muscle,
such as jaw and extraocular muscle, but not in limb or
other body muscle [90,91]. These observations suggest
that Sox6 may play a role in not only determining fiber
types, but also defining developmental maturity and
highly specialized functions of skeletal muscle.
In Sox6 KO muscle, a significant decrease in fast fiber
specific gene expression was also observed. This Sox6
KO phenotype could be a secondary effect of the
increased slow fiber gene products, or could be regu-
lated indirectly by Sox6. Since we did not find Sox6
peaks associated with fast fiber specific genes, both
mechanisms are equally plausible. With regard to indir-
ect regulation, a few possible mechanisms can be
hypothesized. For example, expression of the transcrip-
tion factors Six1 and Six4, activators of fast fiber specific
gene expression [29,92], could be indirectly suppressed
in Sox6 KO muscle during development. Alternatively,
downregulation of fast fiber specific genes in Sox6 KO
muscle could be caused by changes in microRNA
expression. MicroRNAs are known to function as post-
transcriptional regulators of gene expression [93]. A
recent report indicates that microRNAs suppress target
gene expression predominantly through mRNA degrada-
tion [94], thus, it is plausible to postulate that an
increase in microRNAs targeting fast fiber specific genes
in Sox6 KO muscle leads to reduced fast fiber specific
gene mRNA levels. As described above, we found Sox6
binding peaks associated with Myh6 and Myh7 (Addi-
tional file 3, Figure S2B). In the intron sequences of
Myh6 and Myh7, miR-208a and miR-208b are encoded,
respectively [95]. It has been reported that miR-208 sup-
presses expression of THRAP1, which promotes fast
fiber specific gene expression [96]. The increased tran-
scription of Myh6 and Myh7 in Sox6 KO muscle, there-
fore, could lead to upregulation of miR-208, which in
turn, suppress fast fiber specific gene expression. How-
ever, the actual situation is likely to be more complex. It
should be noted that miR-208, along with miR-499, also
targets the 3’-UTR region of Sox6 [68,97,98]. MiR-499 is
encoded in the intron of Myh7b [95,99], which has a
Sox6 binding site in its 5’-upstream region (Additional
file 3, Figure S2C). Since Myh6, Myh7,a n dMyh7b are
all negatively regulated by Sox6 (Figure 5), these data
suggest that Sox6 and these miRNAs constitute two-way
feedback loops.
Figure 9 summarizes both our current results and the
reported regulatory mechanisms for Sox6 expression. A
recent report on the regulation of Sox6 expression in
zebrafish skeletal muscle has demonstrated that Sox6
transcription is positively regulated by MyoD and Myf5,
and repression of Sox6 activity in slow fibers is main-
tained by miR-499 which targets the Sox6 3’-UTR [100].
We have reported that Sox6 transcription is upregulated
when myotube differentiation is induced [13], therefore,
Figure 9 Summary of the present work concerning the fiber
type specification under the control of Sox6. It has been shown
that in zebrafish, MyoD and Myf5 are necessary to activate Sox6
gene expression in muscle [100]. This muscle-specific Sox6
activation mechanism has not been tested in mice yet, but since
Sox6 upregulation coincides with upregulation of these myogenic
regulatory factors during muscle differentiation, it is very likely that
this mechanism is shared in mice also (see text). Once expressed in
muscle, Sox6 directly suppresses transcription of slow fiber specific,
cardiac and embryonic isoform genes during muscle development.
In addition to these structural protein genes, Sox6 suppresses
expression of the transcription factors which have been shown to
activate slow fiber specific genes, Tead1, Tead4, and Prox1. By
unknown mechanisms, fast fiber-specific gene expression in Sox6
KO skeletal muscle is dramatically reduced. Since Sox6 is
preferentially expressed in fast-twitch fiber rich muscles, it is
possible that Sox6 indirectly stimulates the fast fiber-specific gene
program. This idea awaits future investigation. Sox6 activity in slow
fibers is suppressed by miR-499 which is encoded in an intron of
the Myh7b gene. We have shown that Sox6, in turn, suppresses
Myh7b transcription. This negative feedback loop might be
important for fiber type switching during muscle development as
well as in adult muscle.
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scription during mammalian muscle development. Since
MyoD is preferentially expressed in fast fibers in adult
mice [59,60], it may sustain the higher level of Sox6
expression in adult fast fiber muscles reported here as
well as by Quiat et al. [34]. Although the negative regu-
lation of Sox6 by miR-499 has been already reported in
mice [68,97,98], how suppression of Sox6 expression in
slow fibers is initiated is not yet understood. Alterna-
tively, it is also possible that Sox6 expression is activated
when fast-twitch myotubes emerge during fetal muscle
development [101]. Since fiber type-specific gene expres-
sion in mammalian skeletal muscle during development
as well as in adult life is very fluid [2-4], how Sox6
expression is regulated will be an increasingly important
question as we try to understand how muscle fiber type
is initially specified, maintained and changed in rese-
ponse to the external signaling.
Conclusions
We have shown that: (1) Sox6 directly suppresses the
transcription of slow fiber-specific, cardiac, and embryo-
nic isoform genes through binding to the transcriptional
regulatory regions, (2) Sox6 regulates expression of tran-
scriptional regulators critical for muscle development,
therefore, extending its effect on muscle development by
cross-talking with other regulatory pathways, (3) Loss of
Sox6 in skeletal muscle results in a significant increase
in expression of slow fiber-specific, cardiac, and embryo-
nic isoform genes which are associated with Sox6 bind-
ing peaks, accompanied by a decreased in fast fiber-
specific gene expression, and (4) Loss of Sox6 in cardiac
muscle results in increased expression of fetal isoform
genes in the adult heart, which suggests that Sox6 is
required for the postnatal maturation of cardiac muscle
as well. Since the Sox6 KO phenotypes reported here
have relevance to muscle degenerative diseases
[102-105] as well as heart failure [106], uncovering the
many functions of Sox6 in muscle development will




Isolation, culture, and induction of myotube differentia-
tion in differentiation medium (DM) of fetal myoblasts
isolated from mouse E18.5 limb were described pre-
viously [13].
ChIP-seq
ChIP experiments were performed using the Imprint
Chromatin Immunoprecipitation Kit (Sigma-Aldrich)
according to the manufacturer’s instructions. Primary
myotubes differentiated in DM for 48 h were washed
with phosphate-buffered saline with 1 mM MgCl2 (PBS-
M g )o n c e ,a n dt h e nf i x e dw i t h2m Md i s u c c i n i m i d y l
glutarate (DSG; Thermo Fisher Scientific) for 45 min at
room temperature as described by [107]. Cells were
washed with PBS-Mg twice, and fixed further using 1%
formaldehyde for 10 min at room temperature. Antibo-
dies used were rabbit polyclonal antibody to Sox6
(ab30455, Abcam), mouse monoclonal antibody to RNA
Polymerase II (Pol II) CTD repeat YSPTSPS (4H8)
(ab5408, Abcam), and normal mouse IgG from the ChIP
kit. ChIP-seq library was prepared as described pre-
viously [108]. Briefly, the immunoprecipitated material
was end-repaired, A-tailed, ligated to the sequencing
adapters, amplified by 18-cycles of PCR and size selected
(300-600 bp) followed by single end sequencing on an
Illumina Genome Analyzer II by the DNA Technologies
Core Facility at University of California, Davis http://
dnatech.genomecenter.ucdavis.edu/. ChIP-seq data are
available at Gene Expression Omnibus (accession num-
ber GSE32627).
ChIP-seq data analysis
ChIP-seq reads and input sample reads were aligned
using Bowtie (version 0.12.5) [109] with default para-
meters to the mouse NCBI Build 37 genome assembly.
We obtained 3 and 1.5 million uniquely mapped reads
from two independent Sox6 ChIP experiments, and 1.5
and 2.8 million uniquely mapped reads from two inde-
pendent Pol II ChIP experiments, respectively. Peak call-
ing was performed using SISSRs (version 1.4) [110] with
the following parameters. -s (genome size):
2,716,965,481 bp, -F (average length of DNA fragments):
450 bp, -b (background file): input DNA data file of
each ChIP experiment. Common peaks from the two
Sox6 data sets were identified using ChIP-Seq Tool Set
(version 1.0) [111]. Corresponding peaks within 50 bp
were considered as overlapping. Peak annotation was
carried out using PeakAnalyzer [112] with the default
mouse mm9 annotation file. ChIP-seq data was visua-
lized on the UCSC Genome Browser [113]. Motif dis-
covery was conducted using MEME (version 4.5.0) [35]
with default parameters, followed by comparison against
three motif databases (JASPAR, TRANSFAC, and UNIP-
ROBE) using TOMTOM (version 4.5.0) [114]. Gene
ontology (GO) analysis was performed using the Data-
base for Annotation, Visualization and Integrated Dis-
covery (DAVID; http://david.abcc.ncifcrf.gov/) [115,116].
Pol II binding was represented as RPKM (reads per kilo-
base of RefSeq gene region per million mapped reads)
based on read (tag) numbers in peak regions. We used
the 2.8 million read data for calculation and visualiza-
tion to maximize accuracy of result. When there are
multiple RefSeq gene models per gene, the longest gene
model was used for the calculations. When Pol II peaks
An et al. BMC Developmental Biology 2011, 11:59
http://www.biomedcentral.com/1471-213X/11/59
Page 16 of 21were extended to extragenic regions, the length of
extended regions was added to that of RefSeq gene
models.
qPCR
All measurements were conducted with ABI Prism 7900
HT Sequence Detection System (Applied Biosystems).
ChIP-qPCR was performed using Maxima SYBR Green/
ROX qPCR Master Mix (2X) (Fermentas) and specific
primers listed in Additional file 6, Table S3. Single pro-
ducts were confirmed by dissociation curve analysis.
Results were normalized to input, and fold enrichment
was calculated by normalizing to enrichment at a nega-
tive control region (intergenic). RT-qPCR was per-
formed using TaqMan Gene Expression Assays (Applied
Biosystems). Total RNA was extracted with TRIzol
reagent (Invitrogen). Following DNase treatment with
DNA-free Kit (Ambion), cDNA was synthesized using
High Capacity cDNA Reverse Transcription Kits
(Applied Biosystems) with SUPERase-In (Ambion).
TaqMan probes used are provided in Additional file 7,
T a b l eS 4 .R e s u l t sw e r en o r m a l i z e dt ob-actin (Actb)
transcript level. All statistical analyses were performed
using the two-tailed Student’s t-tests. Relative mRNA
levels against b-actin are shown in Additional files 8 and
9, Figures S4 and S5.
Western blotting
Nuclear and cytoplasmic fractionation of primary myo-
blasts and myotubes was carried out using NE-PER
Nuclear and Cytoplasmic Extraction Reagents (Thermo
Fisher Scientific). A total of 30 μg of each protein sam-
ple was loaded on 7.5% SDS-polyacrylamide gel electro-
phoresis and transferred to a nitrocellulose membrane.
The blot was incubated with anti-Nfatc3 mouse mono-
clonal antibody (sc-8405; Santa Cruz Biotechnology) at
1:100, and the signal was detected by Pierce ECL Wes-
tern Blotting Substrate (Thermo Fisher Scientific). To
estimate the amount of protein loaded in each lane, the
same blot was stripped and then incubated with anti-
TATA binding protein (TBP) mouse monoclonal anti-
body (ab818; Abcam) or anti a-Tubulin mouse mono-
clonal antibody (sc-8035; Santa Cruz Biotechnology) at
1:1000.
Plasmid construction
A firefly luciferase expression vector driven by the
MyHC-b promoter (MHCb3500, which contains 3,500
bp of the 5’ upstream sequence of the rat MyHC-b
gene) was kindly provided by Dr. Baldwin at University
of California, Irvine [117,118]. Using this vector as a
template, a Sox motif in the distal Sox6 binding region
found by our ChIP-seq experiments (approx. -2.9 kb in
mouse) was mutated (TACAAAG to TCAGAAG) by an
inverse PCR method [119] using KAPA HiFi HotStart
DNA Polymerase (KAPA Biosystems) to generate
MHCb3500 m ("m” stands for mutation). Firefly lucifer-
ase expression vectors driven by the upstream regions of
Myh7b, Tnni1, and Hdac11 genes (~ 6.0 kb, ~5.2 kb,
and ~1.0 kb, respectively) were generated by inserting
restriction enzyme-digested PCR products into appropri-
ate restriction sites of pGL3-basic vector (Promega). A
firefly luciferase expression vector driven by the first
intron of Tnnc1 gene was constructed by replacing the
CMV enhancer of pTriEx-1.1 vector (Novagen) with the
first intron of Tnnc1 (~1.3 kb) followed by insertion of
a restriction enzyme-digested PCR product of firefly
luciferase gene from pGL3-basic vector into the appro-
priate restriction sites. A Renilla luciferase expresion
vector driven by CMV promoter (pcDNA-Rluc) was
produced by inserting the Renilla luciferase gene, which
was obtained by digesting pRL-TK vector (Promega)
with NheI and XbaI, into pcDNA3.1/Zeo(+) vector
(Invitrogen).
Primers used were listed in Additional file 10, Table
S5.
Reporter assay
The reporter plasmids (see above) were co-transfected
with the Renilla luciferase vector (pcDNA-Rluc) into
mouse fetal primary myoblasts using Lipofectamine
2000 (Invitrogen) at 1:1.5 ratio of DNA and Lipofecta-
mine. Twenty four hours after transfection, cells were
washed with PBS once, and switched to DM. Cells were
incubated further for 48 h, and firefly and Renilla luci-
ferase activities were measured using Dual-Glo Lucifer-
ase Assay System (Promega) and a luminometer
(LumiCount; Packard) according to the manufacturer’s
instructions. Statistical analyses were performed using
the two-tailed Student’s t-tests. As a negative control,
pGL3-basic was used.
Immunohistochemistry
Lower hindlimbs were collected from E18.5 embryos
and one week old mice (P7), and TA and EDL mus-
cles were collected from four month-old mice and
embedded in Tissue Freezing Medium (Triangle Bio-
medical Sciences) for cryostat sectioning. Sections (10
μm) were fixed in 4% paraformaldehyde and processed
for immunohistochemistry. As primary antibodies,
rabbit polyclonal Sox6 antibody (ab30455, Abcam) at
400 fold dilution and mouse monoclonal MyHC-b
antibody at 100 fold dilution (NOQ7.5.4D, Sigma-
Aldrich) were used. As secondary antibodies, Alexa
Fluor 555-conjugated goat anti-rabbit IgG (A-21429,
Invitrogen) and Alexa Fluor 488-conjugated goat anti-
mouse IgG (A-11059, Invitrogen) were used. DAPI
staining was performed to visualize nucleus. Images
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the UC Davis Genome and Biomedical Sciences
Facility.
Animal experiments
The animal studies were carried out under the guidance
issued by the University of California, Davis.
Additional material
Additional file 1: Figure S1 Relative mRNA levels of Sox6, Prox1,
Tead1, Tead4, Tcf4, Hdac9, and Hdac11 in Sox6
f/f muscles. A. Sox6
mRNA levels were determined in the adult EDL, TA, Gas, and Sol muscles
using RT-qPCR and relative expression levels to the soleus in individual
animals were calculated. Three 2 month-old and two three month-old
Sox6
f/f mice were examined (n = 5). The error bars indicate standard
error of the mean. The p-value for differential expression between the
EDL and the soleus was 0.07. B. Prox1 mRNA levels were determined
same as described for Sox6 (n = 3; two 2 month-old and one 3 month-
old Sox6
f/f mice). C-G. For Tead1, Tead4, Tcf4, Hdac9, and Hdac11, data
from EDL, TA, Gas were pooled and compared against soleus (n = 3).
Additional file 2: Table S1 Pol II binding data presented in Figure 4.
Full list of Pol II binding levels to the Sox6 peak-associated genes
measured in RPKM are shown.
Additional file 3: Figure S2 Examples of Sox6 and Pol II binding
events detected by ChIP-seq. ChIP-seq tracks from two data sets of
Sox6 (Sox6-1 and Sox6-2) are shown together with Pol II track (Pol II) of
the 2.8 million read data (see the Methods section for details). Common
Sox6 binding peaks between the two data sets are indicated as black
bars (Sox6 peak). Chromosomal positions (mouse NCBI37/mm9 assembly)
as well as sequence conservation (Vertebrate Cons) are presented above
and below the ChIP-seq plots, respectively. A. Myh1 and Myh2, B. Myh6
and Myh7, C. MyHC7b, D. Tnnc1, E. Tnni1, F. Prox1, G. Sox6, H. Tead1, I.
Tead4, J. Nfatc3, K. Tcf4, L. Hdac9, and M. Hdac11.
Additional file 4: Figure S3 Validation of Sox6 binding. A total of 28
Sox6 peaks identified for the 19 genes discussed in the text were verified
by ChIP-qPCR (ChIP followed by quantitative PCR). The peak profiles are
summarized in Additional file 3, Figure S2A-M. ChIP was performed using
wild type myotubes and Sox6 antibody as described in the Methods
section, and enrichment was quantified by qPCR using the primers
designed to amplify each Sox6 binding site (Additional file 6, Table S3).
As a negative control, an intergenic region without a Sox6 peak was
used. Fold enrichment over a negative control region (Intergenic) are
shown. The intergenic region showed no enrichment. Data are
represented as mean ± SD (n = 3). (*) P < 0.05; (**) P < .005. A.
Enrichment of the Sox6 binding sites associated with sarcomeric protein
genes. B. Enrichment of the Sox binding sites associated with
transcription regulatory genes. Numbers in the parentheses below gene
symbol indicate relative positions (5’ to 3’) of multiple Sox6 binding sites
associated to the gene. For Tcf4, only intragenic binding sites (see
Additional file 3, Figure S2K) were tested.
Additional file 5: Table S2 Biological processes enriched among
genes associated with Sox6 peaks. Full list of Gene Ontology (GO)
biological process terms identified by DAVID are shown.
Additional files 6: Table S3 Primers used for ChIP-qPCR.
Additional files 7: Table S4 TaqMan probes used for RT-qPCR.
Additional file 8: Figure S4 Relative mRNA levels of the genes
presented in Table 1. Relative mRNA levels against b-actin in TA, EDL,
gastrocnemius (Gas), and soleus (Sol) of control (Sox6
f/f) and Sox6
knockout (KO, Sox6
f/f; Myf5-Cre) mice were calculated using the formula
2
-ΔCt. A two and three month-old mice (2 mo and 3 mo, respectively)
were analyzed. A. Relative mRNA level of Sox6. B. Relative mRNA level of
Myh7, Myh4, Ppargc1a, and Sdha.
Additional file 9: Figure S5 Relative mRNA levels of the genes
presented in Table 2and 4. Relative mRNA levels against b-actin in
control (Sox6
f/f) and Sox6 knockout (KO, Sox6
f/f; MCK-Cre) mice were
calculated using the formula 2
-ΔCt. Two 2 month-old mice (mouse ID# 1
and 2) and one 3 old-month mouse (mouse ID# 3) were analyzed. A.
Relative mRNA level of Sox6 in TA, EDL, gastrocnemius (Gas), soleus (Sol),
and the heart. B. Relative mRNA level of contractile protein genes in TA,
EDL, Gas, and Sol. C. Relative mRNA level of transcriptional regulatory
genes in TA, EDL, Gas, and Sol. D. Relative mRNA level of metabolism
related genes and acetylcholine receptor genes in TA, EDL, Gas, and Sol.
E. Relative mRNA level of Myh6, Myh7, Acta1, and Ppargc1a in the heart.
*: not determined. #: undetected.
Additional file 10: Table S5 Primers used for plasmid construction.
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